Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

Ozempic and other GLP-1 drugs have easily become one of the hottest topics in healthcare, especially because they have a ...

If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Because of its dominance in the $150 billion GLP-1 weight-loss and diabetes market, robust financial performance, and innovative pipeline, this ambitious goal is readily attainable, despite ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continue to skyrocket in popularity as both approved and off-label treatments for weight loss. However, their widespread use raises ...

Expanding Medicare coverage for GLP-1RAs could significantly increase spending, despite potential savings from reduced obesity-related comorbidities. A microsimulation model projected a net ...